We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $2.04B
1-Year Est. Return 94.26%
This Fund
S&P 500
This Quarter Est. Return
+21.35%
1 Year Est. Return
+94.26%
3 Year Est. Return
+310.51%
5 Year Est. Return
+306.13%
10 Year Est. Return
+3,783.92%
AUM
$2.04B
AUM Growth
+$120M
Cap. Flow
-$149M
Cap. Flow %
-7.33%
Top 10 Hldgs %
47.27%
Holding
257
New
21
Increased
32
Reduced
47
Closed
104

Top Buys

Rank Stock Value
1
U icon
Unity
U
+$16.4M
2
TRAX
First Tracks Biotherapeutics
TRAX
+$14M
3
SE icon
Sea Limited
SE
+$11.9M
4
NU icon
Nu Holdings
NU
+$10.1M
5
GOSS icon
Gossamer Bio
GOSS
+$9.55M

Top Sells

Rank Stock Value
1
ASTH icon
Astrana Health
ASTH
+$17.6M
2
LLY icon
Eli Lilly
LLY
+$15.3M
3
GXO icon
GXO Logistics
GXO
+$14.8M
4
FOLD
Amicus Therapeutics
FOLD
+$11.2M
5
APLS
Apellis Pharmaceuticals
APLS
+$10.1M

Sector Composition

Rank Sector Weight
1 Miscellaneous 48.9%
2 Healthcare 24.5%
3 Financials 7.3%
4 Consumer Discretionary 7.28%
5 Technology 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLTR icon
1
PUT
Palantir
PLTR
$456B
$283M 13.91%
2,428,700
+100,000
+4% +$13.6M
LLY icon
2
PUT
Eli Lilly
LLY
$1.05T
$185M 9.07%
154,000
+20,000
+15% +$20.4M
NVDA icon
3
PUT
NVIDIA
NVDA
$5.43T
$91.2M 4.48%
456,000
– –
XBI icon
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$85.5M 4.2%
+540,000
New +$73M
COF icon
5
Capital One
COF
$123B
$73.2M 3.6%
365,000
-10,000
-3% -$1.91M
ABBV icon
6
PUT
AbbVie
ABBV
$467B
$61.7M 3.03%
+245,000
New +$52.7M
CVNA icon
7
Carvana
CVNA
$46.8B
$49.4M 2.42%
750,000
-25,000
-3% -$1.77M
MDGL icon
8
PUT
Madrigal Pharmaceuticals
MDGL
$11.9B
$48.3M 2.37%
90,000
– –
ANAB icon
9
AnaptysBio
ANAB
$1.52B
$44.6M 2.19%
660,000
+35,000
+6% +$2.12M
KSPI icon
10
Kaspi.kz JSC
KSPI
$18.2B
$40.7M 2%
470,000
-5,000
-1% -$424K
BDX icon
11
Becton Dickinson
BDX
$50.1B
$37.8M 1.86%
250,000
+25,000
+11% +$3.74M
MOH icon
12
Molina Healthcare
MOH
$9.96B
$37.7M 1.85%
165,000
+5,000
+3% +$906K
PRAX icon
13
PUT
Praxis Precision Medicines
PRAX
$7.84B
$37M 1.82%
110,400
-2,300
-2% -$728K
HGV icon
14
Hilton Grand Vacations
HGV
$2.78B
$36.1M 1.77%
690,000
-85,000
-11% -$4.1M
PTGX icon
15
Protagonist Therapeutics
PTGX
$9.18B
$35.5M 1.75%
290,000
-65,000
-18% -$6.79M
ALNY icon
16
PUT
Alnylam Pharmaceuticals
ALNY
$34.2B
$32.4M 1.59%
107,500
-20,600
-16% -$6.21M
ARKG icon
17
PUT
ARK Genomic Revolution ETF
ARKG
$2.15B
$31.5M 1.55%
750,000
+400,000
+114% +$12.7M
MGTX icon
18
MeiraGTx Holdings
MGTX
$1.05B
$31.1M 1.53%
2,300,000
-150,000
-6% -$1.49M
WVE icon
19
Wave Life Sciences
WVE
$745M
$28.8M 1.41%
4,950,000
+50,000
+1% +$332K
QURE icon
20
uniQure
QURE
$2.65B
$26.5M 1.3%
575,000
+75,000
+15% +$1.96M
IONQ icon
21
PUT
IonQ
IONQ
$18.4B
$25.9M 1.27%
486,700
-45,000
-8% -$2.28M
AMLX icon
22
Amylyx Pharmaceuticals
AMLX
$3.76B
$23M 1.13%
1,279,512
-250,488
-16% -$3.87M
AMTM
23
Amentum Holdings
AMTM
$4.69B
$22.7M 1.12%
1,100,000
+325,000
+42% +$7.86M
TGTX icon
24
TG Therapeutics
TGTX
$8.79B
$21.4M 1.05%
389,081
-200,919
-34% -$8.22M
PHAT icon
25
Phathom Pharmaceuticals
PHAT
$591M
$20.1M 0.99%
1,850,000
– –
1
2 3 4 5

Similar funds

SFI
Siemens Fonds Invest Munich, Germany $2.04B AUM 40.78% 1-Year Est. Return
UF
Univest Financial Souderton, Pennsylvania $2.04B AUM 33.06% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
C
Certuity North Palm Beach, Florida $2.03B AUM 88.59% 1-Year Est. Return
EF
Evanson Financial Mclean, Virginia $2.04B AUM
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return

683 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, 683 Capital Management held 257 positions worth $2.04B, up 6.3% from $1.92B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

683 Capital Management withdrew a net $149M in Q2 2026, closing 104 positions and reducing 47 holdings. Its most notable exit was Eli Lilly, an estimated $15.3M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, up from 47% a quarter earlier, followed by Healthcare and Financials.

Against the trend, 683 Capital Management opened a new position in Unity worth $17.6M.

  • 683 Capital Management's largest Q2 2026 buy was Unity: 615,000 shares worth $17.6M.
  • 683 Capital Management added most to Gossamer Bio in Q2 2026, an estimated $9.55M increase.
  • 683 Capital Management's biggest Q2 2026 reduction was Astrana Health, cutting an estimated $17.6M.
  • 683 Capital Management fully exited Eli Lilly in Q2 2026, selling an estimated $15.3M.
  • 683 Capital Management's ten largest holdings make up 47% of its $2.04B portfolio in Q2 2026.
  • 683 Capital Management opened 21 new positions and closed 104 in Q2 2026.
  • 683 Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.04B.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.